Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 81, Issue 3, Pages 422-432
Publisher
BMJ
Online
2021-12-08
DOI
10.1136/annrheumdis-2021-221575
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland
- (2021) Aron Hjalti Bjornsson et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk factors for COVID‐19 and rheumatic disease flare in a US cohort of Latino patients
- (2021) Alice Fike et al. Arthritis & Rheumatology
- Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
- (2021) Hannah Bower et al. ANNALS OF THE RHEUMATIC DISEASES
- Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
- (2021) Anja Strangfeld et al. ANNALS OF THE RHEUMATIC DISEASES
- Timing of Rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis
- (2021) Luca Quartuccio et al. RHEUMATOLOGY
- Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019
- (2021) Ji-Won Kim et al. KOREAN JOURNAL OF INTERNAL MEDICINE
- Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases
- (2021) Robert Spiera et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of Severe COVID-19 Infection in Patients With Inflammatory Rheumatic Diseases
- (2021) Javier Bachiller-Corral et al. JOURNAL OF RHEUMATOLOGY
- Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy
- (2021) Stefania Spila Alegiani et al. RHEUMATOLOGY
- Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
- (2021) Claire Cook et al. ANNALS OF THE RHEUMATIC DISEASES
- OP0286 CHARACTERISTICS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE (COVID-19 GRA)
- (2021) M. F. Ugarte-Gil et al. ANNALS OF THE RHEUMATIC DISEASES
- LB0002 COVID-19 VACCINE SAFETY IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASE
- (2021) P. M. Machado et al. ANNALS OF THE RHEUMATIC DISEASES
- AB0222 COMPARISON OF SELF-INJECTION DEVICES FOR ADMINISTERING ANTI-TUMOR NECROSIS FACTOR AGENTS USING THE ORIGINAL QUESTIONNAIRE IN PATIENTS WITH RHEUMATOID ARTHRITIS
- (2021) Y. Hirano et al. ANNALS OF THE RHEUMATIC DISEASES
- AB0606 IMPACT OF ABDOMINAL AORTIC CALCIFICATION AND SERUM CREATININE-TO-CYSTATIN C RATIO TO BONE FRAGILITY FRACTURE
- (2021) I. Yoshii ANNALS OF THE RHEUMATIC DISEASES
- AB0546 5 YEARS FOLLOW-UP OF PSORIATIC ARTHRITIS PATIENTS TREATED ACCORDING TREAT-TO-TARGET STRATEGY. PRELIMINARY RESULTS
- (2021) P. Tremaskina et al. ANNALS OF THE RHEUMATIC DISEASES
- Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
- (2021) Giuseppe A Ramirez et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
- (2021) Victoria Furer et al. ANNALS OF THE RHEUMATIC DISEASES
- POS1242 FACTORS ASSOCIATED WITH MORTALITY IN PATIENTS WITH RHEUMATIC DISEASES AND COVID-19 IN MEXICO
- (2021) D. Alpizar-Rodriguez et al. ANNALS OF THE RHEUMATIC DISEASES
- POS1321 MENTAL HEALTH SCREENING IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS
- (2021) S. Eulert et al. ANNALS OF THE RHEUMATIC DISEASES
- AB0634 BELIEFS ABOUT URATE LOWERING THERAPY DIFFER BETWEEN GENERAL PRACTITIONERS AND RHEUMATOLOGISTS
- (2021) F. Veenstra et al. ANNALS OF THE RHEUMATIC DISEASES
- AB0666 PROGNOSTIC VALUE OF SERUM KREBS VON DEN LUNGEN-6 GLYCOPROTEIN CIRCULATING LEVELS IN COVID-19 PNEUMONIA: A PROSPECTIVE COHORT STUDY
- (2021) D. Lobo Prat et al. ANNALS OF THE RHEUMATIC DISEASES
- Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series
- (2021) Caoilfhionn M Connolly et al. ANNALS OF THE RHEUMATIC DISEASES
- POS1260 FACTORS ASSOCIATED WITH SEVERE SARS-COV-2 INFECTION IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES IN MADRID: RESULTS FROM REUMA-COVID SORCOM REGISTRY
- (2021) A. Boteanu et al. ANNALS OF THE RHEUMATIC DISEASES
- Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City
- (2021) Medha Barbhaiya et al. ANNALS OF THE RHEUMATIC DISEASES
- AB0146 HAND AND WRIST ACTIVE RANGE OF MOTIONS AND CONTRIBUTING FACTORS IN RHEUMATOID ARTHRITIS: A CROSS-SECTIONAL STUDY
- (2021) M. He et al. ANNALS OF THE RHEUMATIC DISEASES
- AB0644 EVALUATION OF MONOCYTE TO HIGH-DENSITY LIPOPROTEIN RATIO AND CAROTID INTIMA MEDIA THICKNESS IN GOUT PATIENTS
- (2021) C. Kadiyoran et al. ANNALS OF THE RHEUMATIC DISEASES
- Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab
- (2021) Maurizio Benucci et al. IMMUNOLOGIC RESEARCH
- Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
- (2021) Ana C. Medeiros-Ribeiro et al. NATURE MEDICINE
- Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis
- (2021) Lars Erik Bartels et al. RHEUMATOLOGY INTERNATIONAL
- ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients
- (2021) Andrea Picchianti-Diamanti et al. Frontiers in Immunology
- Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study
- (2021) Cinzia Rotondo et al. Vaccines
- Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
- (2021) Sebastian Eduardo Sattui et al. RMD Open
- Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study
- (2021) Renaud Felten et al. Lancet Rheumatology
- Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies
- (2021) Laura Boekel et al. Lancet Rheumatology
- Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis
- (2021) Andrea Rubbert-Roth et al. Lancet Rheumatology
- COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study
- (2021) Jérôme Avouac et al. Lancet Rheumatology
- BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus
- (2021) Quentin Moyon et al. ANNALS OF THE RHEUMATIC DISEASES
- Impact of hydroxychloroquine used as DMARD on SARS-CoV-2 tests and infection evolution in a population of 871 patients with inflammatory rheumatic and musculoskeletal diseases
- (2021) Ludovic Trefond et al. JOINT BONE SPINE
- Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study
- (2020) Carlo Salvarani et al. ANNALS OF THE RHEUMATIC DISEASES
- Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
- (2020) Milena Gianfrancesco et al. ANNALS OF THE RHEUMATIC DISEASES
- Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis
- (2020) Ennio Giulio Favalli et al. JOURNAL OF RHEUMATOLOGY
- Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors
- (2020) Vega Jovani et al. ANNALS OF THE RHEUMATIC DISEASES
- Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases
- (2020) Jose L Pablos et al. ANNALS OF THE RHEUMATIC DISEASES
- COVID-19 prevalence and the impact on quality of life from stringent social distancing in a single large UK rheumatology centre
- (2020) Natasha Cleaton et al. ANNALS OF THE RHEUMATIC DISEASES
- No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany)
- (2020) Peer Aries et al. ANNALS OF THE RHEUMATIC DISEASES
- COVID-19 in systemic lupus erythematosus: data from a survey on 417 patients
- (2020) Dr. Giuseppe A. Ramirez et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: a population-based study
- (2020) Ho SO et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
- (2020) Xabier Michelena et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- COVID‐19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes
- (2020) Rebecca H. Haberman et al. Arthritis & Rheumatology
- Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions
- (2020) Josep Blanch-Rubió et al. Aging-US
- Correspondence to: ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al
- (2020) Rachael Mary Flood et al. ANNALS OF THE RHEUMATIC DISEASES
- Comment on ‘Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19’ by Konig et al. Long-term exposure to hydroxychloroquine or chloroquine and the risk of hospitalisation with COVID-19: a nationwide, observational cohort study in 54 873 exposed individuals and 155 689 matched unexposed individuals in France
- (2020) Emilie Sbidian et al. ANNALS OF THE RHEUMATIC DISEASES
- Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study
- (2020) Sun-Young Jung et al. CLINICAL MICROBIOLOGY AND INFECTION
- Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark
- (2020) René Cordtz et al. RHEUMATOLOGY
- Association of Race and Ethnicity With COVID‐19 Outcomes in Rheumatic Disease: Data From the COVID‐19 Global Rheumatology Alliance Physician Registry
- (2020) Milena A. Gianfrancesco et al. Arthritis & Rheumatology
- Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19
- (2020) Joht Singh Chandan et al. Arthritis & Rheumatology
- Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS)
- (2016) Martin J Downes et al. BMJ Open
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started